ApolipoproteinA‐I: Insights from redox proteomics for its role in neurodegeneration

Authors:

Abstract
Proteomics has a wide range of applications, including determination of differences in the proteome in terms of expression and post‐translational protein modifications. Redox proteomics allows the identification of specific targets of protein oxidation in a biological sample. Using proteomic techniques, apolipoproteinA‐I(ApoA‐I) has been found at decreased levels in subjects with a variety of neurodegenerative disorders including in the serum and cerebrospinal fluid (CSF) ofAlzheimer disease (AD),Parkinson disease (PD), andDown syndrome (DS) with gout subjects.ApoA‐Iplays roles in cholesterol transport and regulation of inflammation. Redox proteomics further showedApoA‐Ito be highly oxidatively modified and particularly susceptible to modification by 4‐hydroxy‐2‐trans‐nonenal (HNE), a lipid peroxidation product. In the current review, we discuss the consequences of oxidation ofApoA‐Iin terms of neurodegeneration.ROS‐associated chemotherapy relatedApoA‐Ioxidation leads to elevation of peripheral levels of tumor necrosis factor‐α (TNF‐α) that can cross the blood‐brain barrier (BBB) causing a signaling cascade that can contribute to neuronal death, likely a contributor to what patients refer to as “chemobrain.” Current evidence suggestsApoA‐Ito be a promising diagnostic marker as well as a potential target for therapeutic strategies in these neurodegenerative disorders.

This publication has 148 references indexed in Scilit: